📄 Cross-examination of Renee Montgomery (part 4) — Tuesday, May 23, 1995
Address:
C:\DEPT103\CRIMINAL\1995\MAY\23\CROSS-EXAMINATION-OF-RENEE-MON.DOC
TRIAL
▲ Day 80 of 167

Cross-examination of Renee Montgomery (part 4)

Witness: Renee Montgomery
Examiner: Robert Blasier
Called by: Prosecution • Date: Tuesday, May 23, 1995 • Utterances: 412
Defense attorney Robert Blasier cross-examines Cellmark DNA analyst Renee Montgomery on the limitations of the D1S80 PCR-based DNA typing system used in the case. Blasier systematically attacked the reliability of the system—highlighting band mobility problems, subjective interpretation standards, the kit manufacturer's own warnings about degraded samples, and the fact that Montgomery knew the expected genotypes before reading the evidence gels. The examination ended mid-stride as Blasier moved to display photographs of Nicole Brown Simpson's fingernail scrapings and Harmon requested a sidebar.
1 THE COURT:

All right. Miss Montgomery, why don't you step forward.

2 (Brief pause.)
3 THE COURT:

All right. Thank you, ladies and gentlemen. Please be seated. Let the record reflect we have now been rejoined by all the members of our jury panel. And Miss Renee Montgomery is on the witness stand undergoing cross-examination by Mr. Blasier. Mr. Blasier, you may continue with your cross-examination.

4 MR. BLASIER:

Thank you, your Honor. Could we have picture 1175 up again?

5 (Brief pause.)
6 MR. BLASIER:

Miss Montgomery, I just want to clarify that the item--the band-like thing down here that we have been talking about corresponds to the lane at the top for the substrate control, does it not?

7 (No audible response.)
8 MR. BLASIER:

50C?

9 MS. MONTGOMERY:

Yes.

10 MR. BLASIER:

For a Bundy drop?

11 MS. MONTGOMERY:

Correct. I'm sorry. Actually you should also include that extraction blank in the second--or in the lane next to the ladder because since it is right in between those two lanes you need to address both those lanes.

12 MR. BLASIER:

So it could be either one, correct?

13 MS. MONTGOMERY:

Well, I mean that little artifact is right in between the two.

14 MR. BLASIER:

Now, the extraction blank shouldn't show anything either, should it?

15 MS. MONTGOMERY:

Correct.

16 MR. BLASIER:

Okay. Take it down.

17 MR. BLASIER:

I want to ask you a couple of questions about the D1S80 system in general that you talked about on direct. You indicated that it was a discreet allele system, correct?

18 MS. MONTGOMERY:

Correct.

19 MR. BLASIER:

And you indicated that it was--everybody matches some of the bands on the ladder?

20 MS. MONTGOMERY:

No, I don't believe I stated it that way. Umm--

21 MR. BLASIER:

What did you state with respect to the ladder encompassing all the possible alleles?

22 MS. MONTGOMERY:

Okay. The ladder is a composite ladder and that means that from the 14 allele and then the 15 through the 41 allele are present on that. There are alleles that are greater than the 41 and there are also--there is possibility that a 15--a 15 allele has been seen, but it is very rare, and so it is not added into the ladder.

23 MR. BLASIER:

So there are alleles in this system that don't show up on this ladder, correct, because the ladder is too small?

24 MS. MONTGOMERY:

There are some very rare alleles, like I said, greater than 41 and then also the 15 allele that are not on this ladder.

25 MR. BLASIER:

And those are alleles that could be present in someone's DNA that would not show up in this system, correct?

26 MS. MONTGOMERY:

No. That is not correct. They are--they would not have a corresponding ladder allele to call them. If there were something greater than the top 41 allele, and you would see a band up there and I have seen bands greater than 41 and this is very rare and--so anything that is greater than 41 is called greater than 41 and it can't be lined up with any allele ladder. And it happens so infrequently that they have--the company doesn't feel it is necessary to have ladder alleles up in that region, which I agree with.

27 MR. BLASIER:

But the point you indicated is that alleles don't run off the gel. There are alleles in this system that do run off the ladder in the sense that you can't--you can't measure them, correct, with the ladder?

28 MS. MONTGOMERY:

Correct. I just stated that, yes.

29 MR. BLASIER:

Now, when you say a discreet allele system is a good analogy there, comparing a digital watch with an analog watch that goes around, a discrete allele system is like a digital watch, meaning that you are either at one second, two seconds, three seconds, you can't be in between? Is that what you mean by discreet allele?

30 MS. MONTGOMERY:

That--you could use that analogy.

31 MR. BLASIER:

And a clock, for instance, is more like an RFLP system where you can have alleles spread out from the top to the bottom of the gel. They are not going to be in discreet positions?

32 MS. MONTGOMERY:

Or continuous. Or another analogy would be shoe size. When you go in to buy shoes, they have eight and a half, nine, nine and a half, but you might be in between that eight and a half and nine, so for RFLP that is how RFLP is addressed, whereas with D1S80 each person would fit perfectly into that.

33 MR. BLASIER:

And that would be because that everybody who is a 25 has the same sequence of DNA at that location as anybody else that is at 25?

34 MS. MONTGOMERY:

Well, they have the same number of repeats, so an individual that is a 25 would have 25 repeats or an individual that is a 25 would have 25 continuous repeats of that particular sequence. There can be subtle variation, but--and an individual that would be an 18 would have 18 continuous repeats of that region.

35 MR. BLASIER:

Well, when you say there can be subtle variations, what you are saying is that there can be people who show up as a 25, for instance, that have a different sequence than someone else that shows up as a 25, correct?

36 MS. MONTGOMERY:

Oh, yes, that is possible. What we are looking at is length differences; we are not looking at sequence differences with this system.

37 MR. BLASIER:

So two people that come up as a 25 would match in your system, but if they had a different sequence they are different people, aren't they?

38 MS. MONTGOMERY:

Yes, that's true.

39 MR. BLASIER:

So your system does not have the ability, even though you call it a discreet allele system, to identify precisely the sequence in a particular band?

40 MS. MONTGOMERY:

Right. We are looking at length differences.

41 MR. BLASIER:

And unlike PCR and DQ-Alpha, which does identify specific sequences of DNA, correct?

42 MS. MONTGOMERY:

Correct.

43 MR. BLASIER:

So this in a sense is--this aspect of the system is closer to the RFLP system where you are just--you are estimating sequences in a sense, correct?

44 MS. MONTGOMERY:

Well, we are not estimating sequences. We are not not looking at the sequence. We are looking at length differences between individuals, how many repeats they have. It is a 16-base pair repeat, so an individual that is an 18 has 18 of these 16 base pair repeats and they would have a repeat sequence that is, say, this long, whereas an individual that is a 25 would have repeats sequences that are even longer. The same repeat sequence, the same number of repeats, but just a different length.

45 MR. BLASIER:

The point is, different alleles would come up as the same, 25, 24, whatever and they would be different alleles, wouldn't they?

46 MS. MONTGOMERY:

If there is a sequence difference between two individuals, they can run to the same position, but it is the length difference we are looking at, not the sequence difference.

47 MR. BLASIER:

Now, there is also reports in the literature, B bands in the D1S80 system not lining up correctly with the ladder, correct?

48 MS. MONTGOMERY:

That is correct.

49 MR. BLASIER:

And there have been reports in the literature of bands going to a place on the ladder that is different from what the true sequence is, correct?

50 MS. MONTGOMERY:

Going to a place on the ladder different than the true--

51 MR. BLASIER:

I'm sorry?

52 MS. MONTGOMERY:

Repeating your question to myself. There is--if there is a sequence difference, it is possible that there could be just a very subtle variation, but it will still line up with the ladder, the composite ladder allele that is adjacent to it, provided in the Roche kit.

53 MR. BLASIER:

Well, the report--the literature indicates that there are situations where it is so far out of line with the ladder that it can be confused with the band above it?

54 MR. HARMON:

Objection. It is argumentative and it is vague.

55 THE COURT:

Sustained. Rephrase the question.

56 MR. BLASIER:

Are you aware of the literature that talks about the mobility of bands being such that you can mistype which rung of the ladder you are on because the band size is somewhere in the middle?

57 MS. MONTGOMERY:

Yes. That was early on during the development of this system, and what happened is some of the laboratories were trying to use their conventional serology--

58 MR. BLASIER:

Your Honor, I'm going to object as being nonresponsive at this point.

59 THE COURT:

Sustained. Restate your question.

60 THE COURT:

Mobility of bands.

61 MR. BLASIER:

I think she answered. The first part of her answer--I'm satisfied with the first part.

62 THE COURT:

All right.

63 MR. HARMON:

Your Honor, could--that was an explanation, your Honor.

64 THE COURT:

No.

65 MR. HARMON:

Could you read it back? I think you will see it is an explanation.

66 THE COURT:

Counsel, you can cover that on redirect. Proceed.

67 MR. BLASIER:

Now, this system also has a characteristic that if samples are degraded you can lose bands, correct?

68 MS. MONTGOMERY:

You could lose your entire--you could get no results with degraded samples, yes.

69 MR. BLASIER:

You can also selectively lose bands, can't you?

70 MS. MONTGOMERY:

At very, very low levels. It is unusual to lose just--

71 MR. BLASIER:

Is that a yes?

72 MR. HARMON:

Objection, that is argumentative.

73 THE COURT:

Sustained. Rephrase the question.

74 MR. BLASIER:

You can lose--well, let me rephrase it. The ladder that is in the D1S80 system comprises fragment lengths that go from about, what, 300 base pairs up to a couple thousand maybe?

75 MS. MONTGOMERY:

It ranges from a little under 400 base pairs up to over 800 base pairs.

76 MR. BLASIER:

And when a sample degrades it generally starts to break down, the larger fragments get cut--get broken up first, there still may be shorter fragments while the degradation process is going on, correct?

77 MS. MONTGOMERY:

Well, it is a random act that is occurring, the degradation of DNA, and that is just cutting at various locations on the geno.

78 (Discussion held off the record between Defense counsel.)
79 MR. BLASIER:

So your understanding that when degradation occurs and DNA fragments are cut up, they are cut up randomly in the sense that--well, let me rephrase that. When you start chopping up the D.A.--the DNA you lose--

80 THE COURT:

All right. Let's have it quiet in the courtroom, please.

81 MR. BLASIER:

When you start chopping up, the DNA gets cut into successfully smaller pieces?

82 MS. MONTGOMERY:

Yes.

83 MR. BLASIER:

If it fully degrades you may not see any bands at all correct?

84 MS. MONTGOMERY:

Correct.

85 MR. BLASIER:

As it degrades further the bands that are longer, that represent longer sequences, you no longer can see, correct?

86 MS. MONTGOMERY:

That's correct.

87 MR. BLASIER:

So you can lose the upper bands of a genotype? For instance, if somebody is an 18, 31 and the sample is degrading, you could lose the 31 and the person would appear to be an 18, 18, correct?

88 MS. MONTGOMERY:

Well, theoretically that's correct, but from all the method--all the research that has been done and all the studies that have been done, what has been demonstrated is when you get to the level of degradation you typically don't see any result, and if you do see result, you will see something just so faint that you wouldn't be confident even calling that a genotype.

89 MR. BLASIER:

So are you saying that the kit has been developed to the extent that you would not see this particular phenomenon of the upper band disappearing?

90 MS. MONTGOMERY:

Well, it is not the kit that has been developed to do that. It is just studies that have been done within laboratories to demonstrate whether this possibly can occur, and these are environmental abuse studies that have been done.

91 MR. BLASIER:

You are familiar with the perk and Elmer AMP-FLP D1S80 kit manual, are you not?

92 MS. MONTGOMERY:

The product insert?

93 MR. BLASIER:

Yes.

94 MS. MONTGOMERY:

Yes, I am.

95 MR. BLASIER:

And that talks about one of the problems of this system being--one of the interpretation problems, that you may lose larger bands with a degraded sample, does it not?

96 MR. HARMON:

Objection, that calls for hearsay.

97 THE COURT:

Sustained.

98 MR. BLASIER:

Let me show you--let me ask you: Are you aware--let me show you.

99 (Brief pause.)
100 MR. BLASIER:

Are you familiar with that kit insert?

101 MS. MONTGOMERY:

Yes, I am.

102 MR. BLASIER:

And is that what you have in your hand?

103 MS. MONTGOMERY:

Yes, it is.

104 MR. BLASIER:

And do you rely on that in performing the tests that you perform?

105 MS. MONTGOMERY:

Yes. This was their amplification conditions are used in our laboratory for our analysis.

106 MR. BLASIER:

Please look at page 18 section 8.3.1.

107 (Witness complies.)
108 MR. BLASIER:

Have you ever read that section before?

109 MS. MONTGOMERY:

Yes, I have.

110 MR. BLASIER:

Would you agree that that says that you may lose larger bands if a sample is degraded?

111 MS. MONTGOMERY:

What it states is that when you have a single-banded pattern that your results should be interpreted with caution. The--the company has also done some follow-up research in which they've published a paper in May of--

112 MR. BLASIER:

Your Honor, I object. This is not responsive.

113 THE COURT:

All right. Proceed.

114 MR. BLASIER:

And wouldn't you agree that the kit insert also tells you that some alleles don't align up with the ladder, referring to 8.3.2 right below that?

115 MS. MONTGOMERY:

Yes, that's true.

116 MR. BLASIER:

And does that indicate that there are a couple of reasons why that might happen as well?

117 MR. HARMON:

Objection. That calls for hearsay, your Honor.

118 THE COURT:

Overruled.

119 MR. BLASIER:

Are you familiar with the section that I'm talking about, 8.3.2?

120 MS. MONTGOMERY:

Yes.

121 MR. BLASIER:

And that gives several reasons why you might have bands that don't line up the way they are supposed to with the ladder, correct?

122 MS. MONTGOMERY:

Yes, and these are subtle shifts that they are referring to in this section.

123 MR. BLASIER:

Now, the kit also is warranted for amplification of 2.5 nanograms of DNA or more, correct?

124 MS. MONTGOMERY:

Yes. They state in here that they guarantee results with 2.5 nanograms of DNA.

125 MR. BLASIER:

And many of the tests that you ran in this case were on amounts far less than that, correct?

126 (No audible response.)
127 MR. BLASIER:

Or I should say components of mixtures?

128 MS. MONTGOMERY:

Yes. We amplified some samples down to one nanogram.

129 MR. BLASIER:

Now, the D1S80 system is less informative than the RFLP system because it has fewer alleles? Would you agree with that?

130 MS. MONTGOMERY:

Well, we are looking at one region on the D1S80 system whereas with RFLP we are looking at various regions, as Dr. Cotton and Mr. Sims discussed.

131 MR. BLASIER:

Let me break it down then. You are only looking at one location on the geno?

132 MS. MONTGOMERY:

Correct.

133 MR. BLASIER:

One place in the DNA? With RFLP, with a single probe, you are also looking at one location in the DNA, correct?

134 MS. MONTGOMERY:

Correct.

135 MR. BLASIER:

And with RFLP, however, you can have many different alleles, 60, 70, 80 different alleles for a given probe, can you not?

136 MS. MONTGOMERY:

Sure. Yes, you can.

137 MR. BLASIER:

And in the D1S80 system you have a fewer number of possible alleles, correct?

138 MS. MONTGOMERY:

Correct.

139 MR. BLASIER:

So there is less variation among people in the D1S80 system than in the RFLP system because there is fewer possible alleles that you could find in people, correct?

140 MS. MONTGOMERY:

Yes. By comparing D1S80 to RFLP profiles.

141 MR. BLASIER:

Now, the 24 allele is extremely common, is it not?

142 MS. MONTGOMERY:

Yes, the 24 allele is one of the more common alleles.

143 MR. BLASIER:

In fact, over a third of the Caucasian population will have that, correct?

144 (No audible response.)
145 MR. BLASIER:

Approximately?

146 MS. MONTGOMERY:

Yes. I believe approximately thirty percent will have, within their genotype, a 24 or an 18 allele.

147 MR. BLASIER:

And that makes this system in this particular case where both Mr. Simpson and Mr. Goldman have 24 alleles, makes it less informative than if they had more rare alleles, correct?

148 MS. MONTGOMERY:

Well, with Mr. Goldman, he is a 24 homozygote. With Mr. Simpson you need to look at the other allele that goes along with that 24 allele.

149 MR. BLASIER:

My question is when you have a 24 allele it is less--it is a less informative system than if you have a more rare allele, correct, because you can't narrow it down as far in terms of the potential contributors?

150 MS. MONTGOMERY:

Correct. If you had two rare alleles, then it would be more informative, right.

151 MR. BLASIER:

It would be better. And the 18 allele, Nicole Brown Simpson is an 18, 18 and that is always very common allele, is it not?

152 MS. MONTGOMERY:

Correct. By "Very common," as I just stated a few sentences back, that between the 18 and the 24 alleles, you will see this in one--that allele in approximately sixty percent of the population, either the 18 or the 24, but then you also look at the other allele that goes with the individual.

153 MR. BLASIER:

In fact, well if we do that with 18, 18, that is actually a fairly common genotype, is it not, 6 percent of the population has it, Caucasian population?

154 MS. MONTGOMERY:

I would have to refer to my notes for the exact frequency.

155 MR. BLASIER:

Why don't you do that.

156 (Witness complies.)
157 (Brief pause.)
158 MS. MONTGOMERY:

Yes, an 18, 18 occurs in approximately 6 percent of the Caucasian population.

159 MR. BLASIER:

So of a hundred people you would expect there to be six people that would have that combination, Caucasians?

160 MS. MONTGOMERY:

Approximately six out of a hundred.

161 MR. BLASIER:

And that--because that allele is involved, that is much less informative than if you had a rare genotype?

162 MS. MONTGOMERY:

Yes. If you had a rarer one, then you would have less occurrence in the population.

163 MR. BLASIER:

And the fact that Mr. Goldman shares an allele with Mr. Simpson makes it even less informative because there may be some difficulty in assessing who is responsible for the 24 allele? Would you agree with that?

164 MS. MONTGOMERY:

You are talking about mixtures now?

165 MR. BLASIER:

Yes.

166 MS. MONTGOMERY:

And would it be--I'm sorry, could you repeat that?

167 MR. BLASIER:

Because there is an allele in common, that makes it--that makes it more difficult for you to separate components of a mixture because there is one allele that two people have in common? Would you agree with that?

168 MS. MONTGOMERY:

Correct.

169 MR. BLASIER:

Let me ask you to refer to page 91 of your notes.

170 (Witness complies.)
171 MR. BLASIER:

Do you have that in front of you?

172 MS. MONTGOMERY:

I'm afraid I'm going to lose all of them.

173 MR. BLASIER:

Okay.

174 MS. MONTGOMERY:

Okay.

175 MR. BLASIER:

Now, do you and Mr. Sims and the other people in your lab use the same standards to decide whether something is a hint versus a trace versus a C minus versus a C?

176 MS. MONTGOMERY:

As it pertains to D1S80?

177 MR. BLASIER:

Yes.

178 MS. MONTGOMERY:

Yes. There is no standard technology as to hint, trace, for D1S80. So what happens is when someone is second reading the gel, they call it, and if they call it something different than the first analyst, then you document it in your notes. If they aren't calling it a hint, then you write what they are actually calling it.

179 MR. BLASIER:

But the term hint and trace mean different things?

180 (No audible response.)
181 MR. BLASIER:

Correct?

182 MS. MONTGOMERY:

Yes. A hint would be less than a trace.

183 MR. BLASIER:

Okay. And everybody in your lab conforms to that standard?

184 MS. MONTGOMERY:

Typically, yes.

185 MR. BLASIER:

Is that a standard that is set out anywhere in any of the manuals?

186 MS. MONTGOMERY:

No, it is not.

187 MR. BLASIER:

Would you agree that that has a certain subjective element to it? One examiner might call something a hint and another person might call the same thing a trace?

188 MR. HARMON:

Objection, calls for speculation, your Honor.

189 THE COURT:

Overruled.

190 MS. MONTGOMERY:

It is possible. When you get down to those lower levels, umm, a hint would be--a hint uniformly throughout the laboratory by a DNA analyst--case work analyst is something that--there is a hint there. That is an indication that something is there, but you can't be confident that it is actually a band. A trace then uniformly through the lab is there is a band there. It is very, very weak band.

191 MR. BLASIER:

Now, you--on page 91 of your notes, that is a run where you were looking at what types of samples?

192 (No audible response.)
193 MR. BLASIER:

That is your dna-59.

194 MS. MONTGOMERY:

Those are four stains from Mr. Goldman's jeans.

195 MR. BLASIER:

Now, would you agree that on--in your lane no. 12 on your work notes you described that as a 24, 24 with a hint of an 18?

196 MS. MONTGOMERY:

Correct.

197 MR. BLASIER:

And the second reader scored it the same way, correct?

198 MS. MONTGOMERY:

Yes, and also the supervisor who reviewed it scored it the same also.

199 MR. BLASIER:

What did you report that as in your report?

200 (No audible response.)
201 MR. BLASIER:

I ask you to refer to your report at page--I'm sorry, April 6, 1995, page 8 of 11.

202 MS. MONTGOMERY:

That was reported out as a 24 homozygote with a possible trace 18 allele.

203 MR. BLASIER:

What is the difference between a possible trace and a trace and a hint?

204 MS. MONTGOMERY:

Well, a--there is a difference between actually writing your observations on your work sheet and doing your interpretation. Your work sheet is what you actually observed and then you--one needs to think about how they are going to word these reports, and with--I could have written in the report a hypothetical of an 18 allele. But a possible trace, the words sound more effective than a hint of an 18 allele, so the three of us that wrote this report, Mr. Sims, Mr. Myers and myself, discussed it and tried to come up with the correct wording that would adequately describe what we saw. And what we came up with was possible trace, and that is not saying that there is a trace of an 18. That is saying there is possibly a band there but we are not confident in calling it.

205 MR. BLASIER:

When you say you want to do it more effectively, in other words, to put forward the Prosecution's case?

206 MS. MONTGOMERY:

No, not at all. To reflect what the evidence--to reflect what the evidence is. It doesn't matter if it helps the Prosecution or the Defense; we are just reporting the science.

207 MR. BLASIER:

What changed between your reading of the actual film and when you wrote the report to cause you to change the way that was described?

208 MR. HARMON:

Objection, argumentative, assumes facts not in evidence.

209 THE COURT:

Sustained. Rephrase the question.

210 MR. BLASIER:

Did something change in terms of your analysis of this particular test result? Did you read it again? Did something change?

211 MS. MONTGOMERY:

No. To write a hint in a report, it just doesn't--what does a hint mean in a report? Umm, in the laboratory I know what a hint means and I am able to hopefully tell you what a hint means. But in a report, for someone just to pick this report up and be able to read it, whether it is the Prosecution or the Defense, we need to convey what we are trying to get across to them and by saying a possible trace, that conveys that we are not confident that a band exists there, and to just say a hint of an 18, to me it doesn't state it a effectively as saying a possible trace.

212 MR. BLASIER:

Now, unlike RFLP technology, you don't use any kind of computer aids to determine whether there is a band there and whether it is a hint or a trace or possible trace, do you?

213 MS. MONTGOMERY:

No. That is one of the great things about this system. We get to use the basics.

214 MR. BLASIER:

You just look at it and you say looks like a trace to me or looks like a hint to this guy, right?

215 MS. MONTGOMERY:

No. It is all based on one's experience also.

216 MR. BLASIER:

And every analyst that looks at these things always comes up with the same terminology, hint, trace, possible trace?

217 MS. MONTGOMERY:

Well--

218 MR. HARMON:

Objection, calls for speculation, your Honor.

219 THE COURT:

Overruled.

220 MS. MONTGOMERY:

Well, I can't--outside of our laboratory, I'm not quite sure if people would put the same words to these. It is--in our laboratory it is pretty well-defined, and as you could see on this particular one, three different individuals read it and they all came up with the same word, hint, at 18.

221 MR. BLASIER:

Have you ever done any studies where you have looked at different quantities of DNA in a mixture, for instance, to see if--to see what happens when you start reducing the quantity to determine at what point a band becomes an artifact?

222 MS. MONTGOMERY:

Yes, I have done studies to demonstrate at which level or at what level you start losing a minor component.

223 MR. BLASIER:

And have you published any opinion studies that show the differences in intensity of the bands between a hint and a trace and a C minus?

224 MS. MONTGOMERY:

No, I have not.

225 MR. BLASIER:

And there is no scale that you use to do this, is there?

226 MS. MONTGOMERY:

No. It is a scale that is made in our laboratory

227 (Discussion held off the record between Defense counsel.)
228 MR. BLASIER:

I'm sorry?

229 MS. MONTGOMERY:

It is made in our laboratory and it is just a scale, a progression, as I described earlier.

230 MR. BLASIER:

Now, as a sample degrades--have you done any testing to determine what happens when a sample is degraded in terms of how it shows up, whether it shows up as a band or an artifact?

231 MS. MONTGOMERY:

Yes. I did some temperature studies in the laboratory to see what happened when various samples were subjected to various temperatures for differing amounts of time.

232 MR. BLASIER:

It is not like a light switch, is it, where you--it is either there or it isn't there? There are gradiations of band intensities, are there not?

233 MS. MONTGOMERY:

That is true, yes.

234 MR. BLASIER:

You must use your subjective judgment to decide whether something is really a band as opposed to an artifact, correct?

235 MS. MONTGOMERY:

Well, when one gets to the lower level where you are not sure if it is a band, then yes, that's correct.

236 MR. BLASIER:

Now, when you read these things, did you know what genotypes the two victims and Mr. Simpson had?

237 MR. HARMON:

Objection, "These things" as vague, your Honor.

238 THE COURT:

Sustained.

239 MR. BLASIER:

All the evidence samples that you read, when you did that, did you know the genotypes of Mr. Simpson and the two victims?

240 MS. MONTGOMERY:

Yes, I did.

241 MR. BLASIER:

So you knew what results you expected to get, at least as to some of the contributors, correct?

242 MS. MONTGOMERY:

I didn't know what I expected to get, no.

243 MR. BLASIER:

You knew what alleles were common to this case, did you not?

244 MS. MONTGOMERY:

Yes, I did.

245 MR. BLASIER:

You knew these were evidence samples from this case, did you not?

246 MS. MONTGOMERY:

Yes, I did.

247 MR. BLASIER:

You didn't have any kind of expectation in your mind that perhaps these evidence samples would produce these bands?

248 MS. MONTGOMERY:

Well, no, because that is part of testing the evidence, is to show who can be excluded and who can't be excluded.

249 MR. BLASIER:

Do you know--are you familiar with a term examiner bias?

250 MS. MONTGOMERY:

Yes, I have heard that.

251 MR. BLASIER:

What does that mean?

252 MS. MONTGOMERY:

You know, I believe I have only heard it in the context of--let me back up. I--examiner bias I think would be an individual having some bias on their examination.

253 MR. BLASIER:

Have you ever heard it used in the context of one who knows the results they are supposed to get and subconsciously getting the results that they think they are supposed to do, not through any trickery or lying or anything, but you see what you think you are going to see?

KEY QUOTE
254 MS. MONTGOMERY:

So someone could produce bands on the gel? Is that what you are stating?

255 MR. BLASIER:

Someone might interpret one thing as an artifact or as a faint band, depending on what they expect to see?

256 MS. MONTGOMERY:

I'm not aware of that happening, no.

257 MR. BLASIER:

You are not aware of any studies that talk about that particular phenomena?

258 MS. MONTGOMERY:

I haven't read any studies that address that, no.

259 MR. BLASIER:

Now, the--you indicated that the range of size of the fragments in the D1S80 system was about 400 to 800 base pairs?

260 MS. MONTGOMERY:

Roughly, yes.

261 MR. BLASIER:

And the size of the fragments in the DQ-Alpha system are less than 400 base pairs, correct; it is about 240?

262 MS. MONTGOMERY:

Correct, 242.

263 MR. BLASIER:

So would you agree that in a degrading sample you would expect the D1S80 bands to disappear the DQ-Alpha allele from a particular piece of DNA?

264 MS. MONTGOMERY:

Yes. That is possible.

265 MR. BLASIER:

So that if you had a mixed sample, let's say in the DQ-Alpha, you see evidence of a mixture, but you don't see any extra alleles in the D1S80 system, that might be explained by the fact that the sample is degraded?

266 MS. MONTGOMERY:

Yes. And one needs to also look at their yield gel to determine if degradation was occurring on that, if it is possible.

267 MR. BLASIER:

You are aware that the Bundy drops in this case were severely degraded or are you aware of that?

268 MS. MONTGOMERY:

Yes, I believe some of the samples were degraded.

269 MR. BLASIER:

And are you aware of the DQ-Alpha testing results on the steering wheel sample, that is item 29?

270 MS. MONTGOMERY:

Yes, I am.

271 MR. BLASIER:

And you are aware that there was a 4 allele which is inconsistent with a genotype of any of the three people in this case?

272 MS. MONTGOMERY:

Yes, there was a weaker 4 allele detected on the steering wheel sample.

273 MR. BLASIER:

And the reason it was inconsistent is because there was no 1.3 to go along with that which would have been consistent with Ronald Goldman?

274 MS. MONTGOMERY:

Right. There was a very low level amplification--or a low level amplification.

275 MR. BLASIER:

Never tested the steering wheel, item no. 29, with a D1S80 system, did you?

276 MS. MONTGOMERY:

No, we didn't.

277 MR. BLASIER:

There was no efforts made to try and find out what alleles might be present?

278 MS. MONTGOMERY:

No. There wasn't enough DNA present to analyze it by the D1S80 system.

279 MR. BLASIER:

And how do you know that?

280 MS. MONTGOMERY:

Because I remember discussing that issue with Gary Sims at the time that we were doing the analysis on those samples.

281 MR. BLASIER:

How much DNA was present?

282 MS. MONTGOMERY:

I will have to refer to Gary Sims' notes to tell you that.

283 MR. BLASIER:

All right.

284 (Brief pause.)
285 (Discussion held off the record between Defense counsel.)
286 THE COURT:

Miss Montgomery, have you located that item in your notes?

287 MS. MONTGOMERY:

Yes, I have.

288 THE COURT:

All right. Will you give counsel the page reference.

289 MS. MONTGOMERY:

It is on Gary Sims page 40. There is another advantage to numbering pages, I guess.

290 MR. BLASIER:

What page are you referring to?

291 THE COURT:

Gary Sims 40.

292 MR. BLASIER:

36?

293 MS. MONTGOMERY:

40.

294 THE COURT:

Gary Sims 40.

295 MR. BLASIER:

40?

296 MS. MONTGOMERY:

Sorry.

297 (Brief pause.)
298 THE COURT:

All right. Mr. Blasier, do you want to compare your notes with Miss Montgomery's?

299 MR. BLASIER:

Yes.

300 MR. BLASIER:

The quantity was approximately .9, was it not?

301 MS. MONTGOMERY:

Yes, it was.

302 THE COURT:

.9 what? Nanograms?

303 MR. BLASIER:

Nanograms?

304 THE COURT:

Miss Montgomery, nanograms?

305 MS. MONTGOMERY:

Correct. .9 nanograms.

306 (Discussion held off the record between Defense counsel.)
307 MS. MONTGOMERY:

Well, to be--two significant digits Gary wrote 2.86 nanograms.

308 MR. BLASIER:

And you have performed D1S80 tests on amounts less than that, haven't you?

309 MS. MONTGOMERY:

Yes, I have.

310 MR. BLASIER:

So it wasn't a matter of there not being enough to test, was it?

311 MS. MONTGOMERY:

No. It was a matter of there not being enough to test due to the fact that this sample was first used for DQ-Alpha, and after using a portion of it for the DQ-Alpha typing there wasn't enough sample left for D1S80 typing.

KEY QUOTE
312 (Discussion held off the record between Defense counsel.)
313 MR. BLASIER:

Could we have note 95, please.

314 (Brief pause.)
315 MR. BLASIER:

This will be--what are we up to?

316 THE COURT:

This would be 1176. Mrs. Robertson, 1176? Yes. Defense 1176.

317 (Deft's 1176 for id = photograph)
318 MR. BLASIER:

Miss Montgomery, could you look at the monitor and tell me if that appears to be a photograph of your run no. 297?

319 MS. MONTGOMERY:

Yes. Actually this analysis was done by Steve Myers at our laboratory.

320 MR. BLASIER:

And this is--has samples from Nicole Brown Simpson's dress, correct?

321 MS. MONTGOMERY:

Yes, it does.

322 MR. BLASIER:

And the interpretation of this sample for samples G5 and G6 were an 18 allele stronger than a 24 allele?

323 MS. MONTGOMERY:

You are referring to G3?

324 MR. BLASIER:

No, G5 and 6. Let me highlight those at the top. You see G5 and G6?

325 MS. MONTGOMERY:

Yes.

326 MR. BLASIER:

And you agree that that is an accurate picture of that film for that particular run?

327 MS. MONTGOMERY:

Yes, it is, but once--once again, it is difficult to see the weaker components of this and you will actually have to look at the gels yourself.

328 MR. BLASIER:

All right. Let me zoom in on G5 and 6. Would you agree that you cannot see any 24 allele at least on this picture?

329 (No audible response.)
330 MR. BLASIER:

What you see is the 18's, correct?

331 MS. MONTGOMERY:

Correct.

332 MR. BLASIER:

There is nothing apparent here?

333 MS. MONTGOMERY:

Well, this is all done with your computer. I mean, this isn't the actual sample and so I don't know--

334 MR. BLASIER:

Would you look at your original sample and tell me if you agree that it is extremely faint?

335 MS. MONTGOMERY:

(Witness complies.) it is a trace level of 24.

336 MR. BLASIER:

So this is a trace--

337 MS. MONTGOMERY:

But you--

338 MR. BLASIER:

I'm sorry.

339 MS. MONTGOMERY:

But you can see it in here and when you do see a copy of it later on you will be able to see that it is a trace amount of a 24 allele.

340 MR. BLASIER:

How much more is it than a hint?

341 MS. MONTGOMERY:

Well, a hint, as I stated, is a--a hint is a possible. It is not a well-defined band. These trace, these are well-defined bands, they are just very faint, and as far as why you can't see it on your monitor, I can't explain that.

342 (Discussion held off the record between Defense counsel.)
343 MS. MONTGOMERY:

This is the actual copy.

344 MR. BLASIER:

I'm sorry, do you have the actual one there?

345 MS. MONTGOMERY:

Yes, I do.

346 MR. BLASIER:

Could we take a look at that?

347 MS. MONTGOMERY:

Yes, but I would prefer that it not be, umm, put into evidence. Mr. Harmon has a copy of the blue copies.

348 MR. BLASIER:

Well, let me use the blue copy. Is that adequate?

349 MS. MONTGOMERY:

Yes. Mr. Harmon has those copies, I believe.

350 THE COURT:

Mrs. Robertson.

351 MR. BLASIER:

Did we give that a number?

352 THE COURT:

Yes, we did.

353 (Brief pause.)
354 MR. BLASIER:

This is run 297.

355 THE COURT:

297.

356 (Brief pause.)
357 MR. BLASIER:

Can we put--this is exhibit 275-I. Can we put this on the elmo?

358 (Brief pause.)
359 THE COURT:

Mrs. Robertson.

360 (Brief pause.)
361 MR. BLASIER:

I don't think that is the right one.

362 (Brief pause.)
363 THE COURT:

Does it say AG297 on that, Mr. Harris?

364 (Brief pause.)
365 MR. HARRIS:

Yes, it does, your Honor.

366 MS. MONTGOMERY:

I believe it is just backwards or upside down.

367 MR. BLASIER:

Oh, okay.

368 (Brief pause.)
369 MR. BLASIER:

Now, the area of interest--now, the area of interest that we are looking at are the two lanes over toward the right between the two ladders, correct?

370 MS. MONTGOMERY:

Correct.

371 MR. BLASIER:

And you are saying that there is something more than a hint, which is a band at 24?

372 MS. MONTGOMERY:

Correct.

373 MR. BLASIER:

And can we put arrows in that area, Mr. Harris.

374 (Brief pause.)
375 MR. BLASIER:

And can we print that out, please.

376 (Brief pause.)
377 (Discussion held off the record between Defense counsel.)
378 MR. BLASIER:

And I would like to have that shown to the jury, please, if we could mark that printout.

379 THE COURT:

All right. If you will hand--do you want to hand the blue copy--

380 MR. BLASIER:

Maybe we could hand both at the same time.

381 THE COURT:

All right.

382 (Brief pause.)
383 THE COURT:

It takes about three minutes to print that out?

384 (Discussion held off the record between Defense counsel.)
385 MR. BLASIER:

Could we make the printout 1176, please.

386 THE COURT:

1177?

387 MR. BLASIER:

1177.

388 THE COURT:

Or do you want to make the printout 1176-A?

389 MR. BLASIER:

Whatever your pleasure is.

390 THE COURT:

Well, do you want to keep them together?

391 MR. BLASIER:

I think we just have one--that's fine.

392 THE COURT:

All right.

393 MR. BLASIER:

That is a good idea. 1176-A.

394 THE COURT:

All right.

395 (Deft's 1176-A for id = photograph)
396 MR. BLASIER:

Actually, your Honor, let's hold off on that and show another picture and we can do a couple of them at the same time, if that is okay.

397 THE COURT:

Proceed.

398 MS. MONTGOMERY:

Mr.--

399 THE COURT:

I'm sorry.

400 MR. BLASIER:

Could we have photo 92, please?

401 MS. MONTGOMERY:

Could I see that blue copy?

402 MR. BLASIER:

Sure.

403 (Brief pause.)
404 MS. MONTGOMERY:

Thank you.

405 MR. BLASIER:

Your Honor, could this be marked as the next in order?

406 THE COURT:

1177.

407 MR. BLASIER:

1177.

408 (Deft's 1177 for id = photograph)
409 MR. BLASIER:

Now, Miss Montgomery, the picture that we have put up now, 1177, contains the samples from Nicole Brown Simpson's fingernail scrapings, does it not?

410 MS. MONTGOMERY:

Yes, it does.

411 MR. HARMON:

I have an objection, your Honor. May we approach on this? It relates to what Miss Montgomery said a moment ago.

412 THE COURT:

All right. With the court reporter, please.

Temperature

tense

Key Quotes (4)

Ms. Montgomery
the words sound more effective than a hint of an 18 allele, so the three of us that wrote this report, Mr. Sims, Mr. Myers and myself, discussed it and tried to come up with the correct wording that would adequately describe what we saw.
Montgomery inadvertently concedes the lab chose report language for rhetorical effect, giving Blasier an opening to suggest the language was shaped to help the prosecution.
Robert Blasier
Have you ever heard it used in the context of one who knows the results they are supposed to get and subconsciously getting the results that they think they are supposed to do, not through any trickery or lying or anything, but you see what you think you are going to see?
Central examiner-bias attack: Montgomery knew Simpson's and the victims' genotypes before reading evidence samples, raising the specter of unconscious confirmation bias.
Ms. Montgomery
No. It was a matter of there not being enough to test due to the fact that this sample was first used for DQ-Alpha, and after using a portion of it for the DQ-Alpha typing there wasn't enough sample left for D1S80 typing.
Explains why the Bronco steering wheel (item 29) was never tested with D1S80—a gap the defense exploited, given that the DQ-Alpha result on item 29 had shown a 4 allele inconsistent with all three principals.
Ms. Montgomery
No, that is one of the great things about this system. We get to use the basics.
Montgomery frames the absence of computer-aided band-calling as a feature; Blasier immediately turns it against her, highlighting the purely subjective visual judgment involved.

Evidence (8)

Defense 1175
Autoradiograph/gel photograph previously introduced, showing D1S80 substrate control lane for Bundy drop 50C
discussed
Defense 1176
Photograph of run no. 297 (analyzed by Steve Myers), samples from Nicole Brown Simpson's dress (G5 and G6)
introduced, displayed on monitor
Exhibit 275-I
Blue copy of run AG297 gel film — Nicole Brown Simpson dress samples
displayed on Elmo, handed to jury
Defense 1176-A
Printout of run 297 gel image with arrows marking faint 24 allele bands in G5/G6 lanes
introduced
Defense 1177
Photograph of gel run containing samples from Nicole Brown Simpson's fingernail scrapings
introduced, sidebar requested before examination
Informal
Perkin-Elmer AMP-FLP D1S80 kit product insert, sections 8.3.1 and 8.3.2 — warnings about losing larger bands in degraded samples and allele mobility anomalies
discussed; hearsay objection sustained on first attempt, overruled on second
+ 2 more

Notable Exchanges (4)

Robert BlasierMs. Montgomery
Blasier pressed Montgomery on why her worksheet said 'hint of 18' but the April 6 report said 'possible trace 18 allele.' Montgomery explained the three-person team chose language they felt more effectively communicated uncertainty; Blasier suggested this was tailoring language to help the prosecution. Montgomery denied it.
strategic
Robert BlasierMs. Montgomery
Blasier established that Montgomery knew the genotypes of Simpson and both victims before reading the evidence gels, then asked whether she was familiar with 'examiner bias'—the phenomenon of unconsciously seeing what you expect. Montgomery said she was unaware of any studies on that phenomenon.
revealing
Robert BlasierMs. Montgomery
Blasier established that the Bronco steering wheel (item 29) was never tested with D1S80, and that a 4 allele with no accompanying 1.3 had appeared in DQ-Alpha—inconsistent with all three principals. The failure to D1S80-test the steering wheel was attributed to insufficient remaining DNA after DQ-Alpha.
strategic
Robert BlasierMs. Montgomery
Blasier got Montgomery to confirm the kit was warranted for 2.5 nanograms but some evidence samples were amplified down to 1 nanogram, below the manufacturer's guarantee; and separately that the lab had no published or written scale distinguishing 'hint' from 'trace' from 'C minus.'
strategic

Light Moments (3)

Ms. Montgomery
Montgomery, struggling to handle a large stack of notes without dropping them, said 'I'm afraid I'm going to lose all of them.'
Ms. Montgomery
After Montgomery had to locate Gary Sims' page 40 and noted the page number, she quipped: 'There is another advantage to numbering pages, I guess.'
Ms. Montgomery
The gel film (Exhibit 275-I) was put on the Elmo upside down or backwards; Montgomery offered helpfully that she thought it was just reversed.

Credibility Attacks (5)

⚔ Ms. Montgomery
bias / subjective methodology
Blasier established that Montgomery knew the expected genotypes of Simpson and both victims before interpreting evidence samples, raising the specter of examiner bias influencing whether faint bands were called hints, traces, or artifacts.
⚔ Ms. Montgomery
prior inconsistent statement (worksheet vs. report)
Montgomery's contemporaneous worksheet recorded a 'hint of 18' on Goldman's jeans lane 12; the formal report called it 'possible trace 18 allele.' Blasier pressed her on what changed and whether the language shift was designed to favor the prosecution.
⚔ Ms. Montgomery
testing below manufacturer specifications
The D1S80 kit guarantees results at 2.5 nanograms; Montgomery confirmed some evidence samples were amplified at 1 nanogram, undermining confidence in results derived from those samples.
⚔ Ms. Montgomery
lack of written standards / subjective scale
Blasier established that the lab's distinction between 'hint,' 'trace,' 'possible trace,' and 'C minus' was not codified in any manual, had no published validation studies, and was applied subjectively based on individual analyst experience.
⚔ Ms. Montgomery
kit manufacturer's own warnings
Using the Perkin-Elmer product insert (sections 8.3.1 and 8.3.2), Blasier got Montgomery to confirm the manufacturer warned about losing larger alleles in degraded samples and about allele mobility anomalies—problems directly relevant to the heavily degraded Bundy drop samples.

Witness Demeanor

(No audible response.) — repeated several times when questions caught Montgomery off guard or required note-checking
(Witness complies.) — multiple instances of Montgomery consulting notes
(Brief pause.) — frequent pauses throughout, many for exhibit handling

Objections

10 objections (7 sustained, 3 overruled)
Proceeding 6151 • 412 utterances • Prosecution witness
Criminal Trial
Department 103
⚖️ Start
📂 MAY 23, 1995 📄 Cross-examination of Renee Mon
MAY 23, 1995 KRT DvH TD